ENANTA PHARMACEUTICALS INC (ENTA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 09-30. Amounts in USD.

Revenue Quarterly

0 30M 60M 90M Q4 '16: 12.8M Q1 '17: 10.4M Q2 '17: 9M Q3 '17: 7.5M Q4 '17: 75.9M Q1 '18: 38.1M Q2 '18: 44M Q3 '18: 57.3M Q4 '18: 67.2M Q1 '19: 69.9M Q2 '19: 39.6M Q3 '19: 44.4M Q4 '19: 51.3M Q1 '20: 52.6M Q2 '20: 27.6M Q3 '20: 18.7M Q4 '20: 23.6M Q1 '21: 31.7M Q2 '21: 20.1M Q3 '21: 21.6M Q4 '21: 23.6M Q1 '22: 27.6M Q2 '22: 18.7M Q3 '22: 19.5M Q4 '22: 20.3M Q1 '23: 23.6M Q2 '23: 17.8M Q3 '23: 18.9M Q4 '23: 18.9M Q1 '24: 18M Q2 '24: 17.1M Q3 '24: 18M Q4 '24: 14.6M Q1 '25: 17M Q2 '25: 14.9M Q3 '25: 18.3M Q4 '25: 15.1M Q1 '26: 18.6M Q2 '26: 17.2M Q3 '26: 14.4M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '16: -1.1M Q4 '16: -3.1M Q1 '17: -7M Q2 '17: -9.5M Q3 '17: -13.1M Q1 '18: 14.4M Q2 '18: 16.9M Q3 '18: 22.6M Q4 '18: 34.5M Q1 '19: 27.9M Q2 '19: -1.3M Q3 '19: 3.8M Q4 '19: 6.4M Q1 '20: 12.9M Q2 '20: -11.9M Q3 '20: -22.9M Q4 '20: -19.8M Q1 '21: -12.3M Q2 '21: -29.7M Q3 '21: -33.8M Q4 '21: -33.7M Q1 '22: -30.4M Q2 '22: -33.8M Q3 '22: -32.5M Q4 '22: -27M Q1 '23: -30M Q2 '23: -39.5M Q3 '23: -36.7M Q4 '23: -31M Q1 '24: -34.9M Q2 '24: -32.8M Q3 '24: -24.2M Q4 '24: -29.9M Q1 '25: -23.5M Q2 '25: -24.5M Q3 '25: -18.9M Q4 '25: -18.4M Q1 '26: -11.3M Q2 '26: -11.9M Q3 '26: -17.2M Q3 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q4 '16: -1.8M Q1 '17: -5M Q2 '17: -5.4M Q3 '17: -8.4M Q4 '17: 36.5M Q1 '18: 11.7M Q2 '18: 12.6M Q3 '18: 20.3M Q4 '18: 27.4M Q1 '19: 26M Q2 '19: 4.1M Q3 '19: 7M Q4 '19: 9.2M Q1 '20: 13.4M Q2 '20: -6M Q3 '20: -14.3M Q4 '20: -29.3M Q1 '21: -8.3M Q2 '21: -22M Q3 '21: -24M Q4 '21: -24.6M Q1 '22: -30.1M Q2 '22: -33.6M Q3 '22: -31.7M Q4 '22: -26.3M Q1 '23: -29M Q2 '23: -37.7M Q3 '23: -39.1M Q4 '23: -28.1M Q1 '24: -33.4M Q2 '24: -31.2M Q3 '24: -22.7M Q4 '24: -28.8M Q1 '25: -22.3M Q2 '25: -22.6M Q3 '25: -18.3M Q4 '25: -18.7M Q1 '26: -11.9M Q2 '26: -13.1M Q3 '26: -19.5M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q4 '16: -2.1M Q1 '17: 3.1M Q2 '17: -3M Q3 '17: -4.8M Q4 '17: 57.3M Q1 '18: 4.4M Q2 '18: -7.6M Q3 '18: 4M Q4 '18: 28.3M Q1 '19: 30.3M Q2 '19: 30.1M Q3 '19: 2.5M Q4 '19: 8.5M Q1 '20: 12.4M Q2 '20: 14.7M Q3 '20: -4.5M Q4 '20: -15.5M Q1 '21: -14.9M Q2 '21: -4.6M Q3 '21: -29.5M Q4 '21: -21M Q1 '22: -13.3M Q2 '22: -26.4M Q3 '22: -29.6M Q4 '22: -15.5M Q1 '23: -35.6M Q2 '23: -13.8M Q3 '23: -32.1M Q4 '23: -21.6M Q1 '24: -25M Q2 '24: -28.6M Q3 '24: -14.8M Q4 '24: -10.4M Q1 '25: -16.8M Q2 '25: -13.5M Q3 '25: 17.5M Q4 '25: -6.5M Q1 '26: -11.7M Q2 '26: -7.2M Q3 '26: -10M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Free Cash Flow Quarterly

-40M -20M 0 20M 40M 60M Q4 '16: -2.5M Q1 '17: 2.2M Q2 '17: -3.6M Q3 '17: -5.5M Q4 '17: 57.1M Q1 '18: 3.9M Q2 '18: -8.3M Q3 '18: 2.9M Q4 '18: 27.7M Q1 '19: 29.9M Q2 '19: 27.6M Q3 '19: 303K Q4 '19: 8.2M Q1 '20: 11.9M Q2 '20: 14.3M Q3 '20: -4.8M Q4 '20: -15.8M Q1 '21: -15.1M Q2 '21: -4.7M Q3 '21: -29.9M Q4 '21: -21.1M Q1 '22: -13.6M Q2 '22: -26.4M Q3 '22: -29.9M Q4 '22: -17M Q1 '23: -38.8M Q2 '23: -16.2M Q3 '23: -34.3M Q4 '23: -23M Q1 '24: -25.8M Q2 '24: -30.3M Q3 '24: -21.3M Q4 '24: -19.4M Q1 '25: -25.5M Q2 '25: -16M Q3 '25: 17.4M Q4 '25: -7.9M Q1 '26: -11.8M Q2 '26: -7.2M Q3 '26: -10M Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 10M 20M 30M Q3 '13: 17.8M Q1 '14: 17.9M Q2 '14: 18.4M Q3 '14: 19.2M Q1 '15: 19.3M Q2 '15: 19.3M Q3 '15: 19.3M Q1 '16: 19.3M Q2 '16: 18.9M Q3 '16: 19M Q1 '17: 19M Q2 '17: 19M Q3 '17: 19.1M Q1 '18: 19.9M Q2 '18: 20.6M Q3 '18: 21M Q1 '19: 20.8M Q2 '19: 21.1M Q3 '19: 21.1M Q1 '20: 20.8M Q2 '20: 19.9M Q3 '20: 20M Q1 '21: 20.1M Q2 '21: 20.2M Q3 '21: 20.2M Q1 '22: 20.4M Q2 '22: 20.6M Q3 '22: 20.7M Q1 '23: 20.8M Q2 '23: 21M Q3 '23: 21.1M Q1 '24: 21.1M Q2 '24: 21.2M Q3 '24: 21.2M Q1 '25: 21.2M Q2 '25: 21.4M Q3 '25: 21.4M Q1 '26: 28.7M Q2 '26: 29M Q3 '26: 29.1M Q1 '15 Q3 '16 Q2 '18 Q1 '20 Q3 '21 Q2 '23 Q1 '25 Q3 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-7.50 -5.00 -2.50 0.00 2.50 5.00 7.50 Q4 '16: 1.12 Q1 '17: -0.50 Q2 '17: -0.69 Q3 '17: -1.07 Q4 '17: 0.88 Q1 '18: 1.73 Q2 '18: 2.62 Q3 '18: 4.03 Q4 '18: 3.47 Q1 '19: 4.13 Q2 '19: 3.72 Q3 '19: 3.08 Q4 '19: 2.22 Q1 '20: 1.62 Q2 '20: 1.12 Q3 '20: 0.08 Q4 '20: -1.82 Q1 '21: -2.88 Q2 '21: -3.67 Q3 '21: -4.15 Q4 '21: -3.91 Q1 '22: -4.98 Q2 '22: -5.52 Q3 '22: -5.86 Q4 '22: -5.91 Q1 '23: -5.82 Q2 '23: -5.98 Q3 '23: -6.31 Q4 '23: -6.37 Q1 '24: -6.56 Q2 '24: -6.24 Q3 '24: -5.45 Q4 '24: -5.48 Q1 '25: -4.95 Q2 '25: -4.54 Q3 '25: -4.32 Q4 '25: -3.84 Q1 '26: -3.21 Q2 '26: -2.60 Q3 '26: -2.42 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '24 Q2 '25 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.